Literature DB >> 19429733

Diffusion of breast cancer risk assessment in primary care.

Carmen E Guerra1, Melani Sherman, Katrina Armstrong.   

Abstract

BACKGROUND: Physicians who provide primary care to women have the opportunity to identify patients at high risk for breast cancer who are candidates for risk reduction strategies. Our objective was to determine the prevalence and determinants of the adoption of breast cancer risk assessment by primary care physicians.
METHODS: A cross-sectional survey of a nationally representative random sample of 351 internists, family practitioners, and obstetricians-gynecologists. We used a questionnaire that assessed knowledge, attitudes, discussion of breast cancer risk, use of software to calculate breast cancer risk, and ordering of BRCA1/2 testing.
RESULTS: Eighty-eight percent of physicians reported discussing breast cancer risk at least once during the previous 12 months; 48% had ordered or referred a patient for BRCA1/2 testing; and 18% had used a software program to calculate breast cancer risk. Physicians who had used BRCA1/2 testing or discussed breast cancer risk factors were more likely to be obstetrician-gynecologists and not in a solo practice; the use of risk software was also more common among obstetrician-gynecologists but was also associated with having a family member with breast cancer and a greater knowledge about breast cancer risk. Having patients ask for risk information was associated with the discussion of risk factors but not with the other risk assessment strategies.
CONCLUSIONS: Diffusion of breast cancer risk assessment is occurring in primary care practices, with a greater adoption of BRCA1/2 testing than of the use of risk assessment software. Adoption of these strategies seems to be related to the salience of breast cancer personally (for the physician) and within the practice, as well as the size of the practice, rather than attitudes about the risk assessment methods.

Entities:  

Mesh:

Year:  2009        PMID: 19429733      PMCID: PMC2882882          DOI: 10.3122/jabfm.2009.03.080153

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  29 in total

1.  Chart review. A need for reappraisal.

Authors:  L Wu; C M Ashton
Journal:  Eval Health Prof       Date:  1997-06       Impact factor: 2.651

Review 2.  Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.

Authors: 
Journal:  Ann Intern Med       Date:  2005-09-06       Impact factor: 25.391

3.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.

Authors:  F J Couch; M L DeShano; M A Blackwood; K Calzone; J Stopfer; L Campeau; A Ganguly; T Rebbeck; B L Weber
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

4.  Response rates to mail surveys published in medical journals.

Authors:  D A Asch; M K Jedrziewski; N A Christakis
Journal:  J Clin Epidemiol       Date:  1997-10       Impact factor: 6.437

5.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

Authors:  Bernard Fisher; Joseph P Costantino; D Lawrence Wickerham; Reena S Cecchini; Walter M Cronin; Andre Robidoux; Therese B Bevers; Maureen T Kavanah; James N Atkins; Richard G Margolese; Carolyn D Runowicz; Joan M James; Leslie G Ford; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2005-11-16       Impact factor: 13.506

6.  Risk-based recommendations for mammographic screening for women in their forties.

Authors:  M Gail; B Rimer
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

7.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.

Authors:  G Parmigiani; D Berry; O Aguilar
Journal:  Am J Hum Genet       Date:  1998-01       Impact factor: 11.025

8.  Factors affecting breast cancer risk reduction practices among California physicians.

Authors:  Celia Patricia Kaplan; Jennifer S Haas; Eliseo J Pérez-Stable; Genevieve Des Jarlais; Steven E Gregorich
Journal:  Prev Med       Date:  2004-12-10       Impact factor: 4.018

9.  Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction.

Authors:  E B Claus; N Risch; W D Thompson
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

10.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.

Authors:  T S Frank; S A Manley; O I Olopade; S Cummings; J E Garber; B Bernhardt; K Antman; D Russo; M E Wood; L Mullineau; C Isaacs; B Peshkin; S Buys; V Venne; P T Rowley; S Loader; K Offit; M Robson; H Hampel; D Brener; E P Winer; S Clark; B Weber; L C Strong; A Thomas
Journal:  J Clin Oncol       Date:  1998-07       Impact factor: 44.544

View more
  14 in total

1.  Breast Cancer Risk Assessment Among Low-Income Women of Color in Primary Care: A Pilot Study.

Authors:  Emily E Anderson; Silvia Tejeda; Kimberly Childers; Melinda R Stolley; Richard B Warnecke; Kent F Hoskins
Journal:  J Oncol Pract       Date:  2015-06-02       Impact factor: 3.840

2.  Addressing barriers to uptake of breast cancer chemoprevention for patients and providers.

Authors:  Katherine D Crew
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

3.  Tamoxifen vs Raloxifene vs Exemestane for Chemoprevention.

Authors:  Laura Reimers; Katherine D Crew
Journal:  Curr Breast Cancer Rep       Date:  2012-09-01

4.  A feasibility study of breast cancer genetic risk assessment in a federally qualified health center.

Authors:  Kent F Hoskins; Silvia Tejeda; Ganga Vijayasiri; Ifeanyi Beverly Chukwudozie; Mylene H Remo; Hiral A Shah; Ivy E Abraham; Lara E Balay; Tara K Maga; Ericka R Searles; Veena J Korah; Alana Biggers; Melinda R Stolley; Richard B Warnecke
Journal:  Cancer       Date:  2018-10-15       Impact factor: 6.860

Review 5.  Primary care providers' cancer genetic testing-related knowledge, attitudes, and communication behaviors: A systematic review and research agenda.

Authors:  Jada G Hamilton; Ekland Abdiwahab; Heather M Edwards; Min-Lin Fang; Andrew Jdayani; Erica S Breslau
Journal:  J Gen Intern Med       Date:  2016-12-19       Impact factor: 5.128

6.  Barriers in identification and referral to genetic counseling for familial cancer risk: the perspective of genetic service providers.

Authors:  Sharon J Rolnick; Alanna K Rahm; Jody M Jackson; Larissa Nekhlyudov; Katrina A B Goddard; Terry Field; Catherine McCarty; Cynthia Nakasato; Douglas Roblin; Christopher P Anderson; Rodolfo Valdez
Journal:  J Genet Couns       Date:  2011-04-19       Impact factor: 2.537

7.  Pilot study of a culturally sensitive intervention to promote genetic counseling for breast cancer risk.

Authors:  Vida Henderson; Jessica M Madrigal; Le' Chaun Kendall; Pooja Parekh; Jennifer Newsome; Ifeanyi Beverly Chukwudozie; De Lawnia Comer-Hagans; Vickii Coffey; Giesela Grumbach; Shirley Spencer; Carolyn Rodgers; Ravneet Kaur; Lara Balay; Tara Maga; Zo Ramamonjiarivelo; Catherine Balthazar; Robert Winn; Karriem Watson; Angela Odoms-Young; Kent F Hoskins
Journal:  BMC Health Serv Res       Date:  2022-06-25       Impact factor: 2.908

8.  The knowledge value-chain of genetic counseling for breast cancer: an empirical assessment of prediction and communication processes.

Authors:  Nabil Amara; Jolyane Blouin-Bougie; Jalila Jbilou; Norrin Halilem; Jacques Simard; Réjean Landry
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

9.  Accuracy of ovarian and colon cancer risk assessments by U.S. physicians.

Authors:  Laura-Mae Baldwin; Katrina F Trivers; C Holly A Andrilla; Barbara Matthews; Jacqueline W Miller; Denise M Lishner; Barbara A Goff
Journal:  J Gen Intern Med       Date:  2014-02-12       Impact factor: 5.128

10.  Distribution of Estimated Lifetime Breast Cancer Risk Among Women Undergoing Screening Mammography.

Authors:  Bethany L Niell; Bianca Augusto; McKenzie McIntyre; Claire C Conley; Travis Gerke; Richard Roetzheim; Jennifer Garcia; Susan T Vadaparampil
Journal:  AJR Am J Roentgenol       Date:  2021-05-12       Impact factor: 3.959

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.